Investigational drug · Phase 3
KN026
Also called: Placbo
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HER2-positive Gastric Cancer, Advanced Breast Cancer, Resectable HER2-positive Breast Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
7 still active
All registered trials
17
Any phase or sponsor naming "KN026"
First trial start
2022
Apr 7, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KN026", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- HER2-positive Gastric Cancer
- Advanced Breast Cancer
- Resectable HER2-positive Breast Cancer
- Stomach Cancer
- First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
- Early or Locally Advanced HER2-positive Breast Cancer
Approved drugs for the same conditions: Breast cancer · Stomach and esophageal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "KN026" as an intervention, largest first.
- A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast CancerPivotal-lookingRecruiting
Shanghai JMT-Bio Inc.Industry
NCT07441460 · 1,800 participants (planned) · Start Mar 6, 2026 · Primary completion Aug 7, 2034
Drug: KN026; HB1801 and 7 more · For: Resectable HER2-positive Breast Cancer
Sites: Shanghai, China
- Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.Pivotal-lookingRecruiting
Shanghai JMT-Bio Inc.Industry
NCT05838066 · 880 participants (planned) · Start Jul 23, 2023 · Primary completion Jul 31, 2025
Drug: Recombinant Humanized Bispecific antibody against HER2,KN026; HB1801 and 3 more · For: First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
Sites: Beijing, China
- A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast CancerPivotal-lookingActive, not recruiting
Shanghai JMT-Bio Inc.Industry
NCT06747338 · 520 participants (planned) · Start Dec 16, 2024 · Primary completion Dec 16, 2026
Drug: KN026; HB1801 and 4 more · For: Early or Locally Advanced HER2-positive Breast Cancer
Sites: Shanghai, China
- A Study of KN026-based Combination Therapy in HER2-positive Gastric CancerPivotal-lookingNot yet recruiting
Shanghai JMT-Bio Inc.Industry
NCT07332533 · 490 participants (planned) · Start Dec 30, 2025 · Primary completion Jun 30, 2032
Drug: KN026; Capecitabine and 6 more · For: HER2-positive Gastric Cancer
- KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line TherapyPivotal-lookingRecruiting
Shanghai JMT-Bio Inc.Industry
NCT05427383 · 286 participants (planned) · Start Apr 7, 2022 · Primary completion Nov 2025
Drug: KN026/Placbo Injection; Paclitaxel Injection and 2 more · For: Stomach Cancer
Sites: Beijing, China
- JSKN003 Combined Treatment of HER2-positive Gastric CancerPivotal-lookingNot yet recruiting
Shanghai JMT-Bio Inc.Industry
NCT06998771 · 153 participants (planned) · Start Jun 15, 2025 · Primary completion Jun 30, 2028
Drug: JSKN003; KN026 and 5 more · For: HER2-positive Gastric Cancer
- Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid TumorsCompleted
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT04521179 · 102 participants · Start Dec 7, 2020 · Primary completion Jan 12, 2022
Drug: KN026 combination · For: HER2-positive Solid Tumors
Sites: Beijing, China
- KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary CarcinomaNot yet recruiting
Peking University Cancer Hospital & InstituteAcademic, hospital or other
NCT05985707 · 80 participants (planned) · Start Aug 15, 2023 · Primary completion Dec 31, 2026
Drug: KN026; KN046 and 1 more · For: HER2-positive Colorectal Cancer; HER2-positive Biliary Tract Cancer
Sites: Beijing, China
- Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast CancerStatus unknown
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT04165993 · 68 participants · Start Dec 31, 2019 · Primary completion May 27, 2021
Drug: Concurrent chemotherapy and KN026; KN026 monotherapy and 1 more · For: Metastatic Breast Cancer
Sites: Harbin, China
- Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric CancerCompleted
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT03619681 · 63 participants · Start Sep 17, 2018 · Primary completion Jun 30, 2022
Drug: KN026 · For: Breast Cancer; Gastric Cancer
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Case Report: Sustained complete response achieved in a patient with advanced HER-2 positive gastric cancer after 4 years of chemotherapy-free treatment.
Tong X, Peng J, Liu B · Front Oncol 2026
- Placebo Effect on Pain-Related Autonomic Responses in a State of Experimentally-Induced Sensitization.
Allmendinger F, Utz O, Scheuren PS, et al. · Eur J Pain 2026
- Spatial molecular analyses reveal key features associated with response to KN026 in advanced HER2-positive breast cancer.
Ma J, Sun S, Tang X, et al. · Br J Cancer 2026
- Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial.
Liu J, Song C, Yang Y, et al. · Clin Cancer Res 2025
- Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial.
Ma J, Wang J, Xu T, et al. · Cancer Commun (Lond) 2025
- Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II study.
Liu D, Gong J, Li J, et al. · Signal Transduct Target Ther 2025
Also in development for HER2-positive Gastric Cancer
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- JSKN003Phase 37 trials
Shanghai JMT-Bio Inc. · HER2-positive Colorectal Cancer, Advanced Solid Tumor, HER2-positive Gastric Cancer
- HLX22Phase 34 trials
Shanghai Henlius Biotech · HER2 + Breast Cancer, HER2-low Hormone Receptor Positive Breast Cancer, Gastroesophageal-junction Cancer
- PembolizumabpembroPhase 33 trials
Shanghai JMT-Bio Inc. · HER2-positive Gastric Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.